Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.HLXB · Entity 5215 | Director · 10% owner | February 08, 2025 | February 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date February 08, 2025 · Filed February 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 4,480,000 |
Reported balance
After 2025-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-08 · Other · Disposed 30,000 · Balance 4,480,000 F1: . The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date. F2: On February 8, 2025, the Reporting Person transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer. F3: The Reporting Person is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of the Reporting Person and is the managing member of each of the three members of the Reporting Person and has voting and investment discretion with respect to the ordinary shares held of record by Reporting Person. Ms. Chen disclaims any beneficial ownership of the securities held by the Reporting Person other than to the extent of any pecuniary interest she may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: . The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date.
F2: On February 8, 2025, the Reporting Person transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer.
F3: The Reporting Person is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of the Reporting Person and is the managing member of each of the three members of the Reporting Person and has voting and investment discretion with respect to the ordinary shares held of record by Reporting Person. Ms. Chen disclaims any beneficial ownership of the securities held by the Reporting Person other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2025 Filed Feb 10, 2025 17:07 UTC | BridgeBio Oncology Therapeutics, Inc. HLXB · Entity 5215 | OtherClass B Ordinary Shares · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-011813 · ownership.xml · derivative · entry 1 Helix Holdings II LLC · CIK 0001869101 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,480,000 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: . The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date. F2 · kind: On February 8, 2025, the Reporting Person transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer. F1 · derivative.exercise_date: . The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date. F1 · derivative.expiration_date: . The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date. F3 · ownership.direct: The Reporting Person is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of the Reporting Person and is the managing member of each of the three members of the Reporting Person and has voting and investment discretion with respect to the ordinary shares held of record by Reporting Person. Ms. Chen disclaims any beneficial ownership of the securities held by the Reporting Person other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 19:45 UTC | BridgeBio Oncology Therapeutics, Inc. HLXB · Entity 5215 | GrantClass A Ordinary Shares | 509,000 | $10.00 | $5,090,000.00 |
DisclosureSEC source: 0001213900-24-013530 · ownership.xml · nonDerivative · entry 1 Helix Holdings II LLC · CIK 0001869101 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 509,000 F1 · ownership.direct: Helix Holdings II LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the managing members of Helix Holdings II LLC. Bihua Chen is the manager of Helix Holdings II LLC and is the managing member of each of the three members of Helix Holdings II LLC and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings II LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings II LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.